# US 2024/0189426 A1 · Chimeric receptors targeting muc16 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189426 A1
- Document ID: US20240189426A1
- Status: Published application
- Kind: A1
- Application number: 18/588,764
- Filed: 2024-02-27
- Published: 2024-06-13
- Earliest claimed: 2021-08-30
- Assignees: Memorial Sloan Kettering Cancer Center; Sloan-Kettering Institute for Cancer Research; Memorial Hospital for Cancer and Allied Diseases
- Applicants: Memorial Sloan-Kettering Cancer Center; Sloan-Kettering Institute for Cancer Research; Memorial Hospital for Cancer and Allied Diseases
- Inventors: Parwiz ABRAHIMI; Nan CHEN; Renier J. BRENTJENS; Jedd D. WOLCHOK; Taha MERGHOUB
- Web page: https://patentgrep.com/patent/US20240189426A1

## CPC

- A61K 40/4257: {Mucins, e.g. MUC-1}
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/35: Cytokines
- A61K 40/4255: {Mesothelin [MSLN]}
- A61P 35/00: Antineoplastic agents
- C07K 14/54: Interleukins [IL]
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 14/7158: {for chemokines}
- C12N 5/0636: {T lymphocytes}
- A61K 2239/15: Non-antibody based
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The presently disclosed subject matter provides for chimeric receptors that target MUC16 and cells comprising such chimeric receptors. The presently disclosed subject matter further provides uses of the chimeric receptors for treatment.

## Claims

### Claim 1

A chimeric receptor, comprising an extracellular domain, a transmembrane domain, and an intracellular signaling domain, wherein the extracellular domain comprises a mesothelin polypeptide that binds to MUC16 and comprises an amino acid sequence that is at least about 80% identical to the amino acid sequence set forth in SEQ ID NO: 1 or a fragment thereof.

### Claim 2 (depends on 1)

The chimeric receptor of claim 1, wherein the mesothelin polypeptide comprises or consists of an amino acid sequence that is at least about 80% identical to amino acids 296 to 598 of SEQ ID NO: 1 or a fragment thereof.

### Claim 3 (depends on 1)

The chimeric receptor claim 1, wherein the mesothelin polypeptide comprises amino acids 296 to 598 of SEQ ID NO: 1.

### Claim 4 (depends on 1)

The chimeric receptor of claim 1, wherein the mesothelin polypeptide comprises an amino acid sequence that is within Region I of human mesothelin.

### Claim 5 (depends on 1)

The chimeric receptor of claim 1, wherein the mesothelin polypeptide comprises an amino acid sequence that is within Region IAB of human mesothelin.

### Claim 6 (depends on 1)

The chimeric receptor of claim 1, wherein the human mesothelin comprises the amino acid sequence set forth in SEQ ID NO: 1.

### Claim 7 (depends on 6)

The chimeric receptor of claim 6, wherein the Region I comprises amino acids 296 to 390 of SEQ ID NO: 1.

### Claim 8 (depends on 6)

The chimeric receptor of claim 6, wherein the Region IAB comprises amino acids 296 to 359 of SEQ ID NO: 1.

### Claim 9 (depends on 1)

The chimeric receptor of claim 1, wherein the mesothelin polypeptide comprises an amino acid sequence that is at least about 80% identical to the amino acid sequence of amino acids 296 to 359 of SEQ ID NO: 1 or a fragment thereof.

### Claim 10 (depends on 1)

The chimeric receptor of claim 1, wherein the mesothelin polypeptide comprises amino acids 296 to 359 of SEQ ID NO: 1.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The chimeric receptor of any one of claims 1-11, wherein a signal peptide is covalently joined to the N-terminus of the extracellular domain.

### Claim 12 (depends on 1)

The chimeric receptor of claim 1, wherein the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a CD84 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, a ICAM polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 polypeptide, a NKGD polypeptide, a PD-1 polypeptide, a LAG-3 polypeptide, a 2B4 polypeptide, a BTLA polypeptide, or a combination thereof.

### Claim 13 (depends on 1)

The chimeric receptor of claim 1, further comprising a hinge/spacer region.

### Claim 14 (depends on 1)

The chimeric receptor of claim 1, wherein the intracellular signaling domain comprises a CD3ζ polypeptide.

### Claim 15 (depends on 1)

The chimeric receptor of claim 1, wherein the intracellular signaling domain further comprises at least one co-stimulatory signaling region.

### Claim 16 (depends on 1)

The chimeric receptor of claim 1, wherein the at least one co-stimulatory signaling region comprises a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide, or a combination thereof.

### Claim 17 (depends on 1)

A cell comprising the chimeric receptor of claim 1.

### Claim 18 (depends on 17)

The cell of claim 17, wherein the cell comprises an exogenous chemokine receptor or a fragment thereof or an exogenous IL-18 polypeptide or a fragment thereof.

### Claim 19 (depends on 17)

The cell of claim 17, wherein the cell is an immunoresponsive cell.

### Claim 20 (depends on 19)

The cell of claim 19, wherein the cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a B cell, a monocyte, and a macrophage, a stem cell from which a lymphoid cell may be differentiated, a stem cell from which a myeloid cell may be differentiated, and combinations thereof.

### Claim 21 (depends on 20)

The cell of claim 20, wherein the cell is a T cell.

### Claim 22 (depends on 1)

A nucleic acid molecule encoding the chimeric receptor of claim 1.

### Claim 23 (depends on 1)

A nucleic acid composition comprising a first polynucleotide encoding the chimeric receptor of claim 1 and a second polynucleotide encoding a chemokine receptor or an IL-18 polypeptide.

### Claim 24 (depends on 22)

A vector comprising the nucleic acid molecule of claim 22.

### Claim 25 (depends on 22)

A lipid nanoparticle comprising the nucleic acid molecule of claim 22.

### Claim 26 (depends on 22)

A host cell expressing the nucleic acid molecule of claim 22.

### Claim 27 (depends on 17)

A method of reducing tumor burden in a subject having a tumor, increasing or lengthening survival of a subject having a tumor, and/or treating and/or preventing a tumor, comprising administering to the subject the cell of claim 17, wherein the tumor is associated with MUC16.

### Claim 28 (depends on 27)

The method of claim 27, wherein the tumor is selected from the group consisting of ovarian cancer, pancreatic cancer, bladder cancer, lung cancer, stomach cancer, endometrial cancer, breast cancer, colorectal cancer, thyroid cancer, and head and neck squamous cell cancers.

### Claim 29 (depends on 1)

A method for producing a cell comprising a chimeric receptor of claim 1, comprising introducing into the cell a nucleic acid molecule that encodes the chimeric receptor.

### Claim 30 (depends on 17)

A kit for reducing tumor burden in a subject, treating and/or preventing a tumor in a subject, and/or increasing or lengthening survival of a subject having a tumor, comprising the cell of claim 17.
